

해외 바이오의약품 임상 현황 (2020.2.3~2020.2.9)

한국바이오의약품협회, 2020.2.11.
출처: ClinicalTrials.gov

○ 미국 20건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04142983	Tdap Vaccine Safety for Plasma Donors	Tetanus	Biological: Adacel	GCAM Inc.	Phase 2 Phase 3
NCT04255875	Dose Escalation Study of PF-07209326 in Healthy Participants	Healthy	Biological: Placebo Biological: PF-07209326	Pfizer	Phase 1
NCT04251585	Intranasal Insulin in Parkinson's Disease	Parkinson Disease	Drug: Regular Novolin R Drug: Placebo	HealthPartners Institute	Phase 2
NCT04172987	A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants	Healthy	Drug: Tirzepatide Drug: EE/NGM	Eli Lilly and Company	Phase 1
NCT04081337	A Study to Measure Food and Calorie Consumption in Very Overweight Participants Using Tirzepatide	Obesity	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04044209	A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS	Myelodysplastic Syndromes Acute Myeloid Leukemia	Drug: AG-120 Drug: Nivolumab	Yale University	Phase 2
NCT03939585	Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT	Allogeneic Stem Cell Transplant Candidate Acute Myeloid/Lymphoblastic Leukemia Myelodysplastic Syndrome Myeloproliferative Neoplasm Lymphoproliferative Disorders	Biological: Cellular therapy product	Case Comprehensive Cancer Center	Phase 1
NCT04011748	Clinical Application of Stem Cell Educator Therapy in Alopecia Areata	Alopecia Areata Alopecia Totalis Alopecia Universalis	Combination Product: Stem Cell Educator therapy combined with minoxidil	Tianhe Stem Cell Biotechnologies Inc. Yale University Hackensack Meridian Health	Phase 2
NCT04259346	A Study of Two Formulations of Ixekizumab in Healthy Participants	Healthy	Drug: Ixekizumab	Eli Lilly and Company	Phase 1
NCT04227028	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer	Locally Advanced Lung Non-Small Cell Carcinoma Metastatic Lung Non-Small Cell Carcinoma Recurrent Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Biological: Bevacizumab Drug: Brigatinib	Northwestern University National Cancer Institute (NCI)	Phase 1
NCT04256421	A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	Drug: Tiragolumab Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2

○ 영국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2
NCT04256421	A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	Drug: Tiragolumab Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Placebo	Hoffmann-La Roche	Phase 3

해외 바이오의약품 임상 현황 (2020.2.3~2020.2.9)

한국바이오의약품협회, 2020.2.11.
출처: ClinicalTrials.gov

○ 프랑스 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2
NCT04256421	A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	Drug: Tiragolumab Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Placebo	Hoffmann-La Roche	Phase 3

○ 독일 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2
NCT04256421	A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	Drug: Tiragolumab Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT04238962	A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens	Overweight Obesity	Drug: Semaglutide (administered by DV3396 pen-injector) Drug: Semaglutide (administered by PDS290 pen-injector)	Novo Nordisk A/S	Phase 1

○ 중국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04094909	Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC	Staging IV NSCLC	Drug: Rh-endostatin	Guangzhou Institute of Respiratory Disease	Phase 2

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04256421	A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	Drug: Tiragolumab Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Placebo	Hoffmann-La Roche	Phase 3
NCT04145700	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Synovial Sarcoma	Drug: Ramucirumab Drug: Gemcitabine Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04145349	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	Desmoplastic Small Round Cell Tumor	Drug: Ramucirumab Drug: Cyclophosphamide Drug: Vinorelbine	Eli Lilly and Company	Phase 1 Phase 2